Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Urothelial carcinoma trial data presented at ASCO GU 2022

Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, talks on trial data presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers (GU) Symposium 2022. This included data presented on trastuzumab, sacituzumab govitecan and pembrolizumab in patients with urothelial carcinoma (UC) who are platinum refractory, as well as data on trastuzumab, nivolumab and deruxtecan. Dr Rosenburg emphasizes immunotherapy as a treatment to watch for in the future, and to expect to see numerous trials exploring HER2-directed antibody drug conjugates (ADCs), including RC48 that appears to demonstrate high antitumor activity for patients with advanced UC expressing HER2. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.